Schott S, Schneeweiss A, Sohn C
University Hospital Heidelberg, Department of Gynecology and Obstetrics within the National Center for Tumor Diseases, Heidelberg, Germany.
Exp Clin Endocrinol Diabetes. 2010 Nov;118(10):673-7. doi: 10.1055/s-0030-1254116. Epub 2010 Jun 8.
Breast cancer is the leading neoplastic malignancy among females worldwide. Another major health problem in industrial countries is diabetes mellitus type 2, both with a raising tendency. Up to 16% of the elderly breast cancer patients additionally suffer from diabetes. Epidemiologic studies suggest that type 2 diabetes increases breast cancer risk and goes along with an increased mortality however, there has been limited experimental evidence supporting this association. In the present review we summarized epidemiological data on a correlation between diabetes and breast cancer. Further, the diverse hypothesized molecular investigations and purposed mechanisms are recapitulated. The latest discussions on insulin and its enhancement of cancer rates among patients with diabetes have also toughed the breast cancer sector. In contrary, recent data indicate a benefit of breast cancer treatment due to metformin therapy. A large amount of literature is available and provides concepts for future research that is needed to rule out possible overlapping pathomechanism, prognostic factors, therapy interactions as well as possible synergistic or additive or even controversial interaction of chemotherapy and diabetes medication.
乳腺癌是全球女性中最主要的肿瘤性恶性疾病。在工业化国家，另一个主要的健康问题是2型糖尿病，两者都呈上升趋势。高达16%的老年乳腺癌患者还患有糖尿病。流行病学研究表明，2型糖尿病会增加患乳腺癌的风险，并伴随着死亡率的上升，然而，支持这种关联的实验证据有限。在本综述中，我们总结了关于糖尿病与乳腺癌相关性的流行病学数据。此外，还概述了各种假设的分子研究和推测的机制。最近关于胰岛素及其在糖尿病患者中提高癌症发病率的讨论也涉及到了乳腺癌领域。相反，最近的数据表明二甲双胍治疗对乳腺癌治疗有益。有大量文献可供参考，并为未来的研究提供了概念，这些研究需要排除可能重叠的病理机制、预后因素、治疗相互作用以及化疗与糖尿病药物可能的协同、相加甚至有争议的相互作用。
